---
title: "Bank of Marin Bancorp Stock 12‑Month Price Target Raised to $30, Implies 4% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293983560.md"
description: "Bank of Marin Bancorp's average 12-month price target was raised to $30 by five analysts, up from $29.2, implying a 4% upside based on the July 24 closing price. The consensus rating remains 'Buy' among six covering analysts, with three buys, three holds, and no sells."
datetime: "2026-07-27T23:20:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293983560.md)
  - [en](https://longbridge.com/en/news/293983560.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293983560.md)
---

# Bank of Marin Bancorp Stock 12‑Month Price Target Raised to $30, Implies 4% Upside

-   According to estimates from 5 analysts, Bank of Marin Bancorp stock's average price target has risen from $29.2 to $30, with forecasts ranging from $26 to $34 per share
-   Based on the Jul. 24 closing price, the updated target implies approximately 4% potential upside
-   Consensus rating remains at “Buy” across 6 covering analysts, with 3 Buys, 3 Holds and 0 Sells

Explore more price target data and ratings for Bank of Marin Bancorp on the , and track all previous and future analyst recommendations for Bank of Marin Bancorp in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [BMRC.US](https://longbridge.com/en/quote/BMRC.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Bank of Marin director Nicolas C Anderson reports $5,053.7 common share purchase](https://longbridge.com/en/news/294539720.md)
- [Bank of Marin Q2 FY26 net income rises 8.6% to $9.25 million; diluted EPS climbs 9.4% to $0.58](https://longbridge.com/en/news/293933158.md)
- [Are Wall Street Analysts Bullish on Textron Stock?](https://longbridge.com/en/news/296430087.md)
- [Should White Mountains (WTM) Investors React to Strong Q2 Earnings and a Major Share Buyback?](https://longbridge.com/en/news/296004368.md)
- [Should FDA Clearance Of QIAstat-Dx Sepsis Panel Require Action From Qiagen (QGEN) Investors?](https://longbridge.com/en/news/296027748.md)